AHA Coding Clinic® for ICD-9 - 2009 Issue 3; Ask the Editor
Herceptin Therapy for Breast Cancer
A patient had a malignant breast neoplasm excised three years ago and has completed radiation and chemotherapy. Currently there is no evidence of residual disease on exam, on radiographic images or histologically. However, the patient is receiving consolidative treatment for breast cancer with Herceptin indicated for five years. How is maintenance on Herceptin coded? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article addresses a breast cancer coding scenario involving ongoing Herceptin therapy after prior excision, radiation, and chemotherapy. It is intended for coders and billing professionals who need to understand the high-level diagnosis and medication-use coding considerations discussed in the article. The content focuses on maintenance treatment context, cancer status, and the relationship between therapy type and coding assignment.
Why This Topic Matters
Accurate coding for cancer follow-up and ongoing biologic therapy can affect claim accuracy, medical necessity support, and long-term treatment documentation. This article helps readers evaluate a common post-treatment breast cancer scenario without substituting for the full coding guidance.
What You Will Learn
- How the article frames ongoing Herceptin therapy in a breast cancer follow-up context.
- Which broad diagnosis and medication-use concepts are discussed for maintenance treatment.
- How the article distinguishes the therapy type at a high level.
- What documentation context is presented for a post-treatment breast cancer patient.
Who Should Read This
- Medical coders
- Billing specialists
- Compliance staff
- Revenue cycle professionals
- Clinical documentation specialists
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com